Award notice Supplies

Spécialités pharmaceutiques à base de Bosutinib, de Nilotinib et de Axitinib

Notice published in French. The AI analysis summarises it for you in your language.

Official notice and documents

Public buyer: Healthcare Public Procurement (HeCaPP)
Saint-Gilles\Sint-Gillis
Place of performance: 1020 Bruxelles\Brussel, Brussels-Capital
Amount awarded: €266,521 excl. VAT
Planned end of contract: 8 April 2030
likely re-tender around October 2029
Bids received: 2
Procedure: Open procedure
Any company may submit a bid.
Publication: 13 April 2026
Notice language: French

AI analysis: go for it or not?

Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.

Create my free account

Unlimited analyses during the 14-day Pro trial, no card needed.

Description

Spécialités pharmaceutiques à base de Bosutinib, de Nilotinib et de Axitinib

Awarded to

3 lots

Spécialité pharmaceutique à base de Bosutinib
Spécialité pharmaceutique à base de Axitinib
Spécialité pharmaceutique à base de Nilotinib

CPV codes

European codes that classify what the contract is about. They are how we find the tenders for your trade.

33600000

Winning prices for comparable contracts

A quarter below: €269,390
Median: €449,863
A quarter above: €962,736

Amounts awarded (excl. VAT) over the last 3 years for 58 contracts in the same CPV group (3360…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.

Similar contracts already awarded

Contract	Winner	Amount
Farmaceutische specialiteiten op basis van piperacilline/tazobactam, flucloxacilline, linezolid, benzylpenicilline (natrium), vancomycine (hydrochloride), ceftazidime, meropenem (trihydraat), ciprofloxacine en ceftriaxon Healthcare Public Procurement (HeCaPP) · 31 August 2026	Viatris Fresenius Kabi sandoz	€1,646,683
Spécialité pharmaceutique à base de (li)pegfilgrastim Healthcare Public Procurement (HeCaPP) · 18 August 2026	ACCORD HEALTHCARE	€656,000
Spécialités pharmaceutiques à base de glecaprévir/pibrentasvir Healthcare Public Procurement (HeCaPP) · 18 August 2026	Abbvie SA	€2,856,000
spécialités pharmaceutiques à base de solutions de perfusion standard de NaCl 0,9%, de Glucose 5%, de Ringer lactate, de Glucose 10%, de Glucose 5% + NaCl 0,9%, d'eau stérile et de solution d'électrolytes isotonique (sans tampon lactate) et spécialités pharmaceutiques à base de solutions d'irrigation de NaCl 0,9%, de Glycine 1,5% et d'Eau stérile Healthcare Public Procurement (HeCaPP) · 1 July 2026	B. BRAUN MEDICAL BAXTER BELGIUM	€5,294,599
Farmaceutische specialiteiten op basis van fluconazol, voriconazol, anidulafungine, posaconazol en caspofungine Healthcare Public Procurement (HeCaPP) · 29 June 2026	SANDOZ SA Pfizer Fresenius Kabi NV/SA	€186,652

Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 250207-2026.